Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
Date:10/7/2008

jective of the study is to assess the overall tumor response rate to the combination of bavituximab with carboplatin and paclitaxel. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients enrolled in the trial are receiving up to six cycles of bavituximab in combination with carboplatin and paclitaxel. Patients may continue to receive bavituximab alone after completion of the combination regimen cycles as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 182,460 U.S. women will be diagnosed with breast cancer in 2008 and 40,480 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in two separate Phase II combination therapy trials for the treatment of advanced breast cancer and a Phase II combination therapy trial for the treatment of NSCLC. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
4. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
5. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
7. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
8. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
9. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
10. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/17/2014)... December 17, 2014 Los beneficios ... un alto nivel de gasto en investigación y desarrollo ... (finalizado el 30 de septiembre de 2014) ZEISS aumentó ... millones de euros (año anterior: 4.190 millones de euros) ... Las ganancias (EBIT) crecieron un 14 por ciento, a ...
(Date:12/17/2014)... , Dec. 17, 2014 With advancements ... the MRI market is seeing new growth, according ... MRI scans account for the majority of market ... resolution of images, which are creating opportunities for more ... market is growing at a rate of 4%, ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
... LCA-Vision Inc. (NASDAQ: LCAV ), a leading ... Plus ® brand, today reported that 12,444 procedures were ... of 8% compared with 11,497 procedures (60 vision centers) ... first year-over-year quarterly increase in total procedures since the ...
... Companies, Inc. (NYSE: PRX ) announced today that ... Wednesday, November 2, 2011 at 9:00 AM EDT to review ... its financial results on November 2, 2011 before the market ... made via the Company,s website at www.parpharm.com . ...
Cached Medicine Technology:LCA-Vision Reports 2011 Third Quarter Procedure Volume 2
(Date:12/20/2014)... (PRWEB) December 20, 2014 Dress company LunaDress ... dresses, and announced its Christmas Sale, offering big discounts on ... “Every girl has an idea to own a perfect wedding ... for your wedding dress, then come to LunaDress. Many different ... for you. Visit our website now and enjoy the current ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The print ... Post, with a distribution of approximately 160,000 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with the ladies of CTV’s The ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Recently, VogueQueen.com, ... its VogueQueen Big Sale Online for 2015. ... products. All new and old consumers can get a ... order at the company’s website before January 30, 2015. ... prom dresses and launched a prom dress promotion. Many ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer and ... fans. The company has recently updated its official blog ... holiday season, Angeldress Blog has recommended some ... Angeldress.co.uk prides itself in offering a huge selection of ... the company’s outfits are very carefully selected based on ...
(Date:12/20/2014)... San Francisco, CA (PRWEB) December 20, 2014 ... a Social Innovation company just launched first birthday focused ... the services, “MERRY BIRTHDAY MESSAGE” launched in both US ... , MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , ... launching for everyone’s birthday around the world. , Features, ...
Breaking Medicine News(10 mins):Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Atore, Inc. Releasing the First Birthday Portal 2
... Joseph,s Hospital and Medical Center, Phoenix, today announced the ... Inc. for the deployment of the company,s ... system will be used to connect specialist physicians at ... This program will include the Barrow Neurological Institute, as ...
... macular degeneration may have a common cause , , TUESDAY, ... on tests of language, memory and concentration are more ... age-related macular degeneration, a major cause of vision loss, ... a look at the association between cognitive function decline ...
... against bird and seasonal flu viruses , ... at the Dana-Farber Cancer Institute and the Centers ... of human monoclonal antibodies that neutralize an unprecedented ... A (H5N1) virus, previous pandemic influenza viruses and ...
... 12 When Americans were asked to value the ... as they consider spending their own money, they chose ... revealed.The Spectrum Health Value Study(TM) , ... queried a representative sample of Americans over the past ...
... Says It,s Much Worse DALLAS, May 12 The ... will likely paint an extremely bleak future for entitlement ... of dollars. As bad as those projections are, the ... NCPA experts. "The reality is that Medicare and other ...
... Bag(TM) Events Bring Educational Outreach to Senior Centers ... Month ATLANTA, May 12 Eight out of ... problem, such as high blood pressure or diabetes. ... participants take an average of eight or more prescriptions ...
Cached Medicine News:Health News:St. Joseph's Hospital and Medical Center Signs Agreement for Innovative Video Conferencing Use 2Health News:Eye Disease, Cognitive Decline Linked in Study 2Health News:Eye Disease, Cognitive Decline Linked in Study 3Health News:Recent developments at Burnham Institute for Medical Research, May 2009 2Health News:Recent developments at Burnham Institute for Medical Research, May 2009 3Health News:Recent developments at Burnham Institute for Medical Research, May 2009 4Health News:Recent developments at Burnham Institute for Medical Research, May 2009 5Health News:Access to Care Leads Americans' Priorities in First-Ever Public Study of Health Value 2Health News:Access to Care Leads Americans' Priorities in First-Ever Public Study of Health Value 3Health News:The National Council on Aging and CVS/pharmacy Educate Georgia Seniors about Medication Management and Ways to Save Money on Prescription Drugs 2Health News:The National Council on Aging and CVS/pharmacy Educate Georgia Seniors about Medication Management and Ways to Save Money on Prescription Drugs 3Health News:The National Council on Aging and CVS/pharmacy Educate Georgia Seniors about Medication Management and Ways to Save Money on Prescription Drugs 4
... a cruciate sparing version which provides ... both resurfacing and inset patellas. Precision ... and fit with tibial articular surface ... cutting guide peg locations provide easy ...
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results....
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
... The Duracon tibial inserts have radiused ... advanced 4-axis machining, maximizing conformity of ... condyles of the femoral component. The ... the Duracon system, and accommodates the ...
Medicine Products: